SecBot SecBot
8-K ·Filed May 6, 2026

MDGL

MADRIGAL PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001628280-26-030896
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The 127% YoY revenue growth and accelerating patient adds (42,250+) confirm Rezdiffra's blockbuster trajectory. The EPS beat vs consensus is significant, but the widening net loss and $54.3M in one-time BD costs warrant monitoring. Watch for Q2 2026 patient adds and any updates on the oral GLP-1 Phase 1 initiation. The siRNA deal with Arrowhead adds pipeline optionality but near-term focus remains on Rezdiffra's commercial ramp.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$539.73
T+0 close · May 6, 2026 · via day close
Latest settled
−13.42%
T+60 · $467.32
Vs SPY
−15.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $539.73entry
  2. T+1 · 6mo ago −0.90%α −0.57% · $534.86
  3. T+5 · 6mo ago −5.46%α −6.59% · $510.26
  4. T+20 · 6mo ago −9.56%α −12.34% · $488.15
  5. T+60 · 4mo ago −13.42%α −15.48% · $467.32

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consensus revenue estimates of $300.9M. The company posted a GAAP net loss of $94.4M (-$3.25/share), which was narrower than the consensus EPS estimate of -$4.14, driven by strong commercial execution and 42,250+ patients on therapy. Management highlighted blockbuster status on a trailing-12-month basis and a rapidly expanding MASH market, but the company remains unprofitable with rising operating expenses.

Key Financial Metrics

EPS
−$3.25
est −$4.14 · +21.5%
Revenue
$311.3M
est $300.9M · +3.5% · +127.0% YoY
Rating
strong beat

Key Facts

  • Q1 2026 Rezdiffra net sales of $311.3M, up 127% YoY from $137.3M
  • GAAP net loss of $94.4M (-$3.25/share) vs consensus -$4.14 (38% beat)
  • 42,250+ patients on Rezdiffra as of March 31, 2026, up 2.5x from Q1 2025
  • Cash, equivalents, and marketable securities of $817.9M as of March 31, 2026
  • Licensed clinical-stage siRNA asset (ARO-PNPLA3) from Arrowhead Pharmaceuticals on May 5, 2026
  • Operating expenses of $404.1M included $54.3M in one-time upfront business development costs
  • MGL-2086 (oral GLP-1) Phase 1 trial on track to initiate in Q2 2026

Financial Impact

Revenue beat consensus by ~$10.4M (3.5%); EPS beat by $0.89 (21.5% vs consensus -$4.14). Net loss widened YoY due to $54.3M in upfront BD expenses.

revenueepsoperating expensescash position

Risk Factors

  • Net loss widened to $94.4M from $73.2M YoY, driven by $54.3M in upfront BD expenses
  • Operating expenses grew 87% YoY to $404.1M, outpacing revenue growth
  • Cash burn: cash decreased $170.7M from Dec 2025 ($988.6M) to March 2026 ($817.9M)
  • Dependence on single product (Rezdiffra) for all revenue
  • Potential competitive pressure from other MASH therapies in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-030896
Document: mdgl-20260506.htm0001628280-26-030896
Document: 0001628280-26-030896-index-headers.html0001628280-26-030896
Document: 0001628280-26-030896-index.html0001628280-26-030896
Document: 0001628280-26-030896.txt0001628280-26-030896
8-K Data (Synthetic)0001628280-26-030896

Track record

18 reports on MDGL

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  3. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  4. Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  5. Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  6. Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  7. Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  8. Nov 3, 202613d ago 8-K Bullish 7/10 No price data
  9. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
  10. Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026